AUTOIMMUNE thyroid disorders are significantly more common in patients with systemic lupus erythematosus (SLE), but they do not appear to worsen disease outcomes, according to a recent case-control ...

Introduction Pregnant women with SLE have an increased risk of maternal complications and adverse fetal outcomes. These include pre-eclampsia, preterm birth and fetal growth restriction. Interestingly ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

In this month’s episode, we speak with Dr. Jane Salmon about Antiphospholipid Syndrome, or APS. Dr. Salmon is a Collette Kean Research Professor and the director of the Lupus and APS Center of ...

More information: Diagnostic overshadowing in systemic lupus erythematosus (SLE): A qualitative study, Lupus (2025). DOI: 10.1177/09612033251345184 ...

There aren’t any medicines that treat lupus fog specifically. But many people find that their lupus fog is worse during flares — so treatments that help to prevent or treat lupus flares may also help ...

MECHANICSVILLE, Va. — For Terrina Williams, drawing is more than just a hobby — it's a path to healing. Each intricate mark made on paper helps her cope with the chronic pain caused by lupus ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK drugmaker plows billions into the growing area of cell therapy called ...

Monogenic lupus nephritis (LN) differs substantially from non-monogenic LN in clinical presentation, renal severity, and progression to end-stage kidney disease (ESKD), underscoring the importance ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in systemic lupus erythematosus, according to data presented at the EULAR 2025 ...

The primary endpoint, which was measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment/BICLA at Week 48, showed positive results. It’s important to note that the ...

Gazyva has also been filed for the lupus nephritis indication in Europe, said Roche, which is also expecting a readout from the phase 3 ALLEGORY trial in a broader SLE population later in 2025 and ...